Candidate Gene Polymorphisms and Response to Rituximab-CHOP in Patients With Diffuse Large Cell Lymphoma
Upon enrollment in the study, patients will have a blood sample collected for genotyping of
the FCGR3A gene (immunoglobulin Fc G receptor IIIa), the ABCB1 gene (ATP Binding Cassette
Beta 1; also called MDR1), and other candidate genes. Patients will be treated with R-CHOP
for six cycles, which is standard therapy for advanced stage DLCL. Response will be
monitored by an FDG-PET scan performed after 2 cycles of R-CHOP and restaging exams
performed upon completion of chemotherapy. Gene polymorphisms will be analyzed to establish
which polymorphisms predict response to R-CHOP.
Interventional
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label
Negative [F-18]fluorodeoxyglucose-positron emission tomography (FDG-PET) scan after 2 cycles of R-CHOP
Approximately 42 days (2 cycles of R-CHOP)
No
Amanda Cashen, MD
Principal Investigator
Washington University School of Medicine
United States: Institutional Review Board
05-0122
NCT00590941
February 2005
April 2011
Name | Location |
---|---|
Washington University School of Medicine | Saint Louis, Missouri 63110 |